Precipio, Inc. (NASDAQ:PRPO – Get Free Report) was the recipient of a large decrease in short interest during the month of June. As of June 15th, there was short interest totalling 1,200 shares, a decrease of 14.3% from the May 31st total of 1,400 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 4,200 shares, the days-to-cover ratio is currently 0.3 days.
Precipio Trading Up 3.7 %
Shares of PRPO stock traded up $0.19 during mid-day trading on Monday, hitting $5.38. 1,490 shares of the company’s stock were exchanged, compared to its average volume of 5,452. Precipio has a fifty-two week low of $4.65 and a fifty-two week high of $8.99. The stock has a 50-day simple moving average of $5.74 and a two-hundred day simple moving average of $6.13. The company has a quick ratio of 0.62, a current ratio of 0.78 and a debt-to-equity ratio of 0.01. The stock has a market cap of $7.91 million, a price-to-earnings ratio of -1.57 and a beta of 1.41.
Precipio (NASDAQ:PRPO – Get Free Report) last posted its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($1.46) earnings per share (EPS) for the quarter. Precipio had a negative return on equity of 46.12% and a negative net margin of 31.00%. The business had revenue of $3.43 million for the quarter.
About Precipio
Precipio, Inc, a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels.
Read More
- Five stocks we like better than Precipio
- Using the MarketBeat Dividend Tax Calculator
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Stock Market Sectors: What Are They and How Many Are There?
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with MarketBeat.com's FREE daily email newsletter.